Flutazolam
Flutazolam.svg
Flutazolam ball-and-stick.png
Clinical data
Trade namesCoreminal (JP)
Other names13-chloro- 2-(2-fluorophenyl)- 9-(2-hydroxyethyl)- 3-oxa- 6,9-diazatricyclo[8.4.0.02,6] tetradeca-1(10),11,13- trien- 8-one
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
Legal status
Legal status
  • US: Unscheduled
  • In general: unscheduled, ℞-only in Japan
Pharmacokinetic data
MetabolismHepatic
Elimination half-life3.5 hours (parent compound); 47-100 hours (major metabolite)
Identifiers
  • 10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-3,5-dihydro-2H-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H18ClFN2O3
Molar mass376.81 g·mol−1
3D model (JSmol)
  • Fc1ccccc1C42OCCN2CC(=O)N(c3c4cc(Cl)cc3)CCO
  • InChI=1S/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2 checkY
  • Key:WMFSSTNVXWNLKI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Flutazolam[1] (Coreminal, MS-4101) is a drug which is a benzodiazepine derivative. It was invented in Japan, and this is the main country in which it has been used medically. It has sedative, muscle relaxant, anticonvulsant, and anxiolytic effects similar to those produced by other benzodiazepine derivatives, and though it is around the same potency as diazepam, it produces a more marked sedation and impaired coordination. It is indicated for the treatment of insomnia.[2] Its major active metabolite is n-desalkylflurazepam, also known as norflurazepam, which is also a principal metabolite of flurazepam (trade name Dalmane).[3] While flutazolam has a very short half-life of only 3.5 hours, n-desalkylflurazepam has a long half-life of between 47-100 hours.[4]

Flutazolam is closely related in structure to another benzodiazepine, haloxazolam.[5][6]

See also

References

  1. ^ DE 1952486 
  2. ^ Mitsushima T, Ueki S. Psychopharmacological effects of flutazolam (MS-4101). Nippon Yakurigaku Zasshi. 1978 Nov;74(8):959-79. (Japanese).
  3. ^ Miyaguchi H, Kuwayama K, Tsujikawa K, Kanamori T, Iwata YT, Inoue H, Kishi T (February 2006). "A method for screening for various sedative-hypnotics in serum by liquid chromatography/single quadrupole mass spectrometry". Forensic Science International. 157 (1): 57–70. doi:10.1016/j.forsciint.2005.03.011. PMID 15869852.
  4. ^ "Dalmane Prescribing Information" (PDF). Prescribing Information for Dalmane. FDA. Retrieved 3 April 2022.
  5. ^ Kuwayama T, Kurono Y, Muramatsu T, Yashiro T, Ikeda K (January 1986). "The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution". Chemical and Pharmaceutical Bulletin (Tokyo). 34 (1): 320–6. doi:10.1248/cpb.34.320. PMID 2870816.
  6. ^ Yashiro T, Kuwayama T, Kawazura H, Suzuki T (October 1987). "[The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system]". Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan (in Japanese). 107 (10): 830–4. doi:10.1248/yakushi1947.107.10_830. PMID 2894449.